Buy & Sell Summit Therapeutics Inc (SMMT) – Summit Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $14.58BMarket Cap
- HealthSector
- -38.91%3M Drawdown
- $14.01BEnterprise Value
- -Dividend Yield
- 72% Buy | 28% SellTrading Activity
- 5 daysTypical Hold Time
Summit Therapeutics Inc (SMMT) is currently valued at a market capitalization of $14.58B, with an enterprise value of $14.01B. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $13.85 and a high of $29.32, highlighting its annual price range. Over the past three months, Summit Therapeutics Inc has recorded a drawdown of -38.91%, reflecting recent price volatility. On average, investors hold Summit Therapeutics Inc for approximately 5 days, indicating typical investor behavior on the platform.
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Most Recent News
Class action deadlines near for investors in ATRA, COTY, SMCI, and IBRX over alleged securities fraud.
Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in securities fraud class actions against Atara Biotherapeutics, Coty Inc., Super Micro Computer, and ImmunityBio. The lawsuits allege these comp...
Buscar Company advances key permits for Treasure Canyon gold mine in California.
Buscar Company announced significant progress in obtaining permits for its Treasure Canyon Mine project in Plumas County, California. Several permits, including a burn permit and dust control plan, have been approved, while other applications are und...
Investigations launched into fairness of merger deals for Veris, XOMA, Organon, and RE/MAX shares.
Brodsky & Smith LLC has announced investigations into whether the boards of Veris Residential, XOMA Royalty Corporation, Organon & Co., and RE/MAX Holdings breached their fiduciary duties in recent merger agreements. The investigations focus on wheth...